Abstract
Stool gluten immunogenic peptide (s-GIP) measurement is an innovative tool for detecting voluntary and involuntary gluten exposure in patients with coeliac disease. However, the optimal strategy for its clinical use remains unclear. This longitudinal, prospective study evaluated stool sampling twice a week over 28 days, comparing average s-GIP concentrations with reduced sampling strategies to optimise its clinical application. Testing stool twice within 7 days was practical and accurate for monitoring dietary adherence. This approach effectively balances patient convenience with diagnostic accuracy for routine clinical use.
